Undisclosed mAb Biosimilar Portfolio

About BioXpress Therapeutics

BioXpress Therapeutics is a private, Switzerland-based biosimilar developer founded in 2014, operating in a pre-revenue, pre-clinical to clinical stage. The company leverages a specialized team and a partnership-driven model to develop monoclonal antibody biosimilars for oncology and immunology, aiming to reduce drug costs and increase treatment access. Its strategy emphasizes high-quality development under EMA standards and forming alliances with other biopharma companies to accelerate programs. Key risks include intense biosimilar competition, complex development pathways, and execution challenges in a capital-intensive sector.

Therapeutic Areas